ATE325125T1 - Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden - Google Patents

Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden

Info

Publication number
ATE325125T1
ATE325125T1 AT03754461T AT03754461T ATE325125T1 AT E325125 T1 ATE325125 T1 AT E325125T1 AT 03754461 T AT03754461 T AT 03754461T AT 03754461 T AT03754461 T AT 03754461T AT E325125 T1 ATE325125 T1 AT E325125T1
Authority
AT
Austria
Prior art keywords
furanopyrrolyl
thienopyrrolyl
histamine
compounds
receptor ligands
Prior art date
Application number
AT03754461T
Other languages
English (en)
Inventor
Hui Cai
Nicholas I Carruthers
Curt A Dvorak
James P Edwards
Annette K Kwok
Jianmei Wei
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE325125T1 publication Critical patent/ATE325125T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT03754461T 2002-09-06 2003-09-05 Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden ATE325125T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40872302P 2002-09-06 2002-09-06

Publications (1)

Publication Number Publication Date
ATE325125T1 true ATE325125T1 (de) 2006-06-15

Family

ID=31978666

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03754461T ATE325125T1 (de) 2002-09-06 2003-09-05 Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden

Country Status (12)

Country Link
US (3) US7226938B2 (de)
EP (1) EP1543011B1 (de)
JP (1) JP4596915B2 (de)
AT (1) ATE325125T1 (de)
AU (1) AU2003272285A1 (de)
CA (1) CA2497868C (de)
CY (1) CY1105080T1 (de)
DE (1) DE60305052T2 (de)
DK (1) DK1543011T3 (de)
ES (1) ES2264534T3 (de)
PT (1) PT1543011E (de)
WO (1) WO2004022537A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7226938B2 (en) * 2002-09-06 2007-06-05 Janssen Pharmaceutica, N.V. Heterocyclic compounds
GB0222912D0 (en) * 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222909D0 (en) * 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
US20080102476A1 (en) * 2003-09-26 2008-05-01 Lars Karlsson Analyzing Histamine H4 Receptor-Mediated Effects In Whole Blood
CZ2006427A3 (cs) * 2003-12-29 2006-11-15 Sepracor Inc. Pyrrolové a pyrazolové inhibitory DAAO
ATE405549T1 (de) 2004-06-18 2008-09-15 Biolipox Ab Zur behandlung von entzündungen geeignete indole
EP1776982A1 (de) * 2005-10-18 2007-04-25 Argenta Discovery Limited Pyrimidine Derivate als Modulator der Histamine Rezeptor
EP1812113A1 (de) * 2004-11-11 2007-08-01 Argenta Discovery Limited Pyrimidin-verbindungen als histaminmodulatoren
CA2587141A1 (en) * 2004-11-24 2006-06-01 Pfizer Inc. Octahydropyrrolo[3,4-c]pyrrole derivatives
EP1671972A1 (de) * 2004-11-24 2006-06-21 Pfizer Limited Octahydropyrrolo[3,4-c]pyrrol-Derivate
KR20070114123A (ko) 2005-01-19 2007-11-29 바이올리폭스 에이비 염증 치료에 유용한 인돌
MX2008000250A (es) 2005-07-06 2008-03-19 Sepracor Inc Combinaciones de eszopiclona y trans-4-(3,4-diclorofenil)-1,2,3,4- tetrahidro-n-metil-1-naftalenamina o trans 4-(3,4-diclorofenil)-1, 2,3,4-tetrahidro-1-naftalenamina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y
EP1767537A1 (de) * 2005-09-21 2007-03-28 Cellzome (UK) Ltd. Pyrimidinverbindungen für die Behandlung entzündlicher Erkrankungen
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
AU2007205114B2 (en) 2006-01-06 2012-11-08 Sunovion Pharmaceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
ES2566479T3 (es) 2006-01-06 2016-04-13 Sunovion Pharmaceuticals Inc. Inhibidores de reabsorción de monoamina con base en tetralona
CN101421228B (zh) 2006-03-31 2014-05-21 塞普拉柯公司 手性酰胺和胺的制备
PT2007752E (pt) 2006-03-31 2010-10-18 Janssen Pharmaceutica Nv Benzoimidazol-2-il pirimidinas e pirazinas como moduladores do receptor de histamina h4
US20090069343A1 (en) * 2006-04-10 2009-03-12 Dunford Paul J Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus
US20080058395A1 (en) * 2006-06-30 2008-03-06 Sepracor Inc. Fused heterocyclic inhibitors of D-amino acid oxidase
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
MX2008016525A (es) * 2006-06-30 2009-03-09 Sepracor Inc Inhibidores heterocíclicos fusionados de d-amino ácido oxidasa.
US7579370B2 (en) 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
US7985745B2 (en) 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
WO2008047821A1 (fr) 2006-10-18 2008-04-24 Takeda Pharmaceutical Company Limited Composé hétérocyclique fusionné
WO2008074445A1 (en) * 2006-12-18 2008-06-26 Ucb Pharma, S.A. Novel tricyclic and heterotricyclic derivatives, processes for preparing them, pharmaceutical compositions thereof
MX2009007410A (es) * 2007-01-18 2009-09-09 Sepracor Inc Inhibidores de d-aminoacido oxidasa.
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
US8669291B2 (en) 2007-05-31 2014-03-11 Sunovion Pharmaceuticals Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
CA2727627C (en) * 2008-06-12 2018-02-13 Janssen Pharmaceutica Nv Use of histamine h4 antagonist for the treatment of post-operative adhesions
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
WO2010017418A1 (en) * 2008-08-07 2010-02-11 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
EP2201982A1 (de) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamin-H4-Rezeptorantagonisten zur Behandlung von Vestibularisstörungen
EP2460794A4 (de) * 2009-07-31 2013-01-23 Shionogi & Co Pharmazeutische zusammensetzung mit einem kondensierten hetero-ring-derivat
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
HUE039713T2 (hu) 2012-06-08 2019-02-28 Sensorion H4 receptor inhibitorok tinnitus kezelésére
MY180726A (en) 2013-03-06 2020-12-08 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
TW201729810A (zh) 2015-10-26 2017-09-01 札爾科製藥公司 嘧啶組成物、其超純組成物及鹽類、製造彼之方法、及使用彼於治療組織胺h4受體(h 4 )仲介之疾病與病情之方法
CN109499595B (zh) * 2018-11-16 2021-10-08 中国林业科学研究院林产化学工业研究所 一种氧还原反应（orr）催化剂gpncs及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2571723B1 (fr) * 1984-10-12 1988-08-26 Lipha Derives de thieno et furo-(2,3-c) pyrroles, procedes de preparation et medicaments les contenant
NZ223654A (en) 1987-03-09 1990-03-27 Janssen Pharmaceutica Nv 1-alkyl-substituted-benzimidazole-4-piperidinamines and pharmaceutical compositions
GB9803228D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
EP1088824B1 (de) 1999-09-30 2004-01-07 Pfizer Products Inc. Bicyclische Pyrrolylamide als Glycogenphosphorylase-Inhibitoren
EP1136071A3 (de) 2000-03-22 2003-03-26 Pfizer Products Inc. Verwendung von Glykogen-Phosphorylase-Hemmern
JP4544820B2 (ja) 2001-03-09 2010-09-15 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 複素環化合物
US7226938B2 (en) * 2002-09-06 2007-06-05 Janssen Pharmaceutica, N.V. Heterocyclic compounds

Also Published As

Publication number Publication date
CA2497868A1 (en) 2004-03-18
PT1543011E (pt) 2006-08-31
ES2264534T3 (es) 2007-01-01
AU2003272285A1 (en) 2004-03-29
JP4596915B2 (ja) 2010-12-15
AU2003272285A8 (en) 2004-03-29
DE60305052T2 (de) 2006-12-21
CY1105080T1 (el) 2009-11-04
WO2004022537A3 (en) 2004-05-06
US20070185131A1 (en) 2007-08-09
CA2497868C (en) 2010-11-30
US7645758B2 (en) 2010-01-12
US20040048878A1 (en) 2004-03-11
US20070185120A1 (en) 2007-08-09
JP2006500394A (ja) 2006-01-05
EP1543011B1 (de) 2006-05-03
EP1543011A2 (de) 2005-06-22
DK1543011T3 (da) 2006-08-07
DE60305052D1 (de) 2006-06-08
US7226938B2 (en) 2007-06-05
WO2004022537A2 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
DE60305052D1 (de) Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden
BR0314059A (pt) Compostos heterocìclicos
NO20052591L (no) Pyridopyrolizin og pyridoindolizinderivater
DE602006007556D1 (de) Heteroarylsulfonylstilbene als 5-ht2a-antagonisten
DE602005009745D1 (de) Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
EA200700262A1 (ru) Арилидены для лечения заболеваний, опосредуемых эстроген-родственным рецепторам альфа
DE60215000D1 (de) DIHYDROPYRROLOi1,2-AöINDOL- UND TETRAHYDROPYRIDOi1,2-AöINDOLDERIVATE ALS PROSTAGLANDIN REZEPTOR ANTAGONISTEN
NO20080475L (no) Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
ATE478856T1 (de) Spirobenzodioxole und deren verwendung als cb1- antagonisten
SE0202241D0 (sv) Novel Compounds
ATE413392T1 (de) Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
ATE538119T1 (de) Benzothiazolcyclobutylamin-derivate und deren verwendung als histamin-3-rezeptor-liganden
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
DE60329330D1 (de) Piperidin- und pyrrolidin-derivate alsantagonisten des histamin-h3-rezeptors
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
ATE340785T1 (de) 2-phenylamino-4-trifluoromethyl-5-(benzyl- oder pyridin-4-ylmethyl)carbamoylpyrimidin-derivate als selektive cb2 cannabinoid-rezeptor modulatoren
ATE402924T1 (de) Pyridiniumsalze und deren verwendung
EA200801240A1 (ru) Новые способы получения производных циклопропиламида
ATE486078T1 (de) 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc- chemokinrezeptors
ATE453628T1 (de) Nucleosidderivate und deren therapeutische verwendung
ATE496047T1 (de) Phenylen-bis-oxazolidin-derivate und ihre verwendung als antikoagulantien
ATE390427T1 (de) Diazabicylononan - und decanderivate und ihre verwendung als opioid-rezeptorligande
ATE490269T1 (de) Kristallstruktur der trypanosoma cruzi proline racemase (tcpraca) und verwendung davon
DE60330373D1 (de) Piperidinderivate als ccr5-inhibitoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1543011

Country of ref document: EP